PK/PD Support for Drug Approvals

Certara Strategic Consulting provides high-quality, regulatory-complaint PK/PD analyses that are the basis of your regulatory submission package. On more than 100 client engagements per year, our pharmacometricians apply our world-class expertise and technology to support nonclinical and clinical study analysis for new drug approvals.

We use the latest versions of Phoenix® WinNonlin®, Phoenix NLME™, IVIVC Toolkit™ for Phoenix WinNonlin, and the Phoenix Knowledgebase Server™ Online (PKS™ Online) to ensure that your analyses are carried out to the highest professional standards, in minimum time, at competitive rates.

PK/PD Analysis Using Industry-Standard Phoenix WinNonlin

  • Noncompartmental analysis (NCA) - sparse or rich data analysis
  • Compartmental analysis - semi-physiological PK/PD modeling

Early Clinical Studies

  • Phase I - MTD, SAD, MAD, BA/BE, Food Effect, DDI studies; studies in special populations (e.g., renal and hepatic impaired patients), QT prolongation studies
  • Phase II - Studies in patients for dosing requirements (Phase IIa) and efficacy (Phase IIb)

In Vivo-In Vitro Correlation (IVIVC) Using IVIVC Tookit for Phoenix WinNonlin

  • Modified-release formulation and Super Generics [505(b)(2) submissions]
  • Fixed-Dose Combination (>2 products combined into 1 tablet formulation)
  • Drug delivery systems (e.g., transdermal, parenteral, pulmonary)


Our methods are simple, efficient, and robust. You receive the highest quality analysis, leading to protocols optimized for:

  • Number of samples - a key cost driver
  • Sampling schedule - to improve your picture of PK
  • Dose
  • Population

We can support your strategic drug development decisions and new drug approvals through quantitative analysis and predictive models of diseases, drugs and clinical trials.